The European Society of Gastrointestinal Endoscopy (ESGE) has published a position statement on the role of gastrointestinal endoscopy in screening for digestive tract cancers.
Key recommendations include the following:
For average-risk populations, ESGE recommends population-based faecal immunochemical testing (FIT) screening programmes for individuals 50-75 years with average risk for colorectal cancer (CRD)
In high-risk populations, endoscopic screening for gastric cancer should be considered for individuals aged >40 years. Its use for intermediate risk should be based on local settings.
For oesophageal and pancreatic cancer, endoscopic screening should be considered only in high-risk individuals:
For squamous cell carcinoma, in those with a personal history of head and neck cancer, achalasia, or previous caustic injury.
For Barrett’s oesophagus (BE)-associated adenocarcinoma, in those with long-standing (>5 years) gastro-oesophageal reflux disease symptoms (GORD) and multiple risk factors (age ≥50 years, white race, male sex, obesity, first-degree relative with BE or oesophageal adenocarcinoma [EAC].
For pancreatic cancer screening, endoscopic ultrasound may be used in selected high-risk patients such as those with a strong family history and/or genetic susceptibility.